COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK

被引：0
|
作者：
Schlueter, M. [1 ]
Vega-Hernandez, G. [2 ]
Wojcik, R. [1 ]
机构：
[1] IMS Hlth, London, England
[2] Novo Nordisk Ltd, Gatwick, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1886
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A675 / A675
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    Nguyen, Hai V.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 3030 - 3039
  • [32] Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
    Lee, W. C.
    Conner, C.
    Hammer, M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 897 - 906
  • [33] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Ehlers, Lars Holger
    Lamotte, Mark
    Monteiro, Sofia
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    DIABETES THERAPY, 2021, 12 (05) : 1523 - 1534
  • [34] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Lars Holger Ehlers
    Mark Lamotte
    Sofia Monteiro
    Susanne Sandgaard
    Pia Holmgaard
    Evan C. Frary
    Niels Ejskjaer
    Diabetes Therapy, 2021, 12 : 1523 - 1534
  • [35] Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom
    Bennett, Hayley
    Tank, Amarjeet
    Evans, Marc
    Bergenheim, Klas
    McEwan, Phil
    DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1047 - 1055
  • [36] INCRETIN THERAPY FOR PATIENTS WITH TYPE 2 DIABETES IN SPAIN: A COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN
    Ramirez de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
  • [37] Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
    M. Charokopou
    P. McEwan
    S. Lister
    L. Callan
    K. Bergenheim
    K. Tolley
    R. Postema
    R. Townsend
    M. Roudaut
    BMC Health Services Research, 15
  • [38] Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    BMC HEALTH SERVICES RESEARCH, 2015, 15
  • [39] The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
    van der Linden, N.
    Van Olst, S.
    Nekeman, S.
    Uyl-de Groot, C. A.
    DIABETIC MEDICINE, 2021, 38 (04)
  • [40] Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
    Chuang, L. H.
    Verheggen, B. G.
    Charokopou, M.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1127 - 1134
12345